Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development.

导出 OA

翻译打印收藏纠错

作者： Meina,Liang ^[1] ; Martin,Schwickart ^[1] ; Amy K,Schneider ^[1] ; Inna,Vainshtein ^[1] ; Christopher,Del Nagro ^[1] ; Nathan,Standifer ^[1] ; Lorin K,Roskos ^[1]

作者单位： Department of Clinical Pharmacology and DMPK, Medimmune, LLC, Mountain View, California, 94043. ^[1]

关键词 PKPD relationship animal and human studies biopharmaceutical clinical trial dose selection drug development flow cytometry pharmacodynamic biomarker receptor occupancy target binding

主题词药物发现(Drug Discovery);流式细胞术(Flow Cytometry);人类(Humans);药代动力学(Pharmacokinetics)

DOI 10.1002/cyto.b.21259

PMID 26054054

发布时间 2021-01-09

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览56

Cytometry. Part B, Clinical cytometry

2016年90卷2期

117-27页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development.

Cytometry. Part B, Clinical cytometry

相似文献

Cytometry. Part B, Clinical cytometry

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development.

Cytometry. Part B, Clinical cytometry

相似文献

Cytometry. Part B, Clinical cytometry

相关期刊

检索历史清除